

# Non-small cell lung cancer with a single metastasis, the new stage M1b; does the site matter?

Citation for published version (APA):

Vanfleteren, M. J. E. G. W., Hendriks, L. E. L., Weijnen, M. J. C., Voo, S. A., Hochstenbag, M. M. H., & Dingemans, A. M. C. (2017). Non-small cell lung cancer with a single metastasis, the new stage M1b; does the site matter? *Cancer Treatment and Research Communications*, 13, 1-2.  
<https://doi.org/10.1016/j.ctarc.2017.07.003>

## Document status and date:

Published: 01/01/2017

## DOI:

[10.1016/j.ctarc.2017.07.003](https://doi.org/10.1016/j.ctarc.2017.07.003)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:


[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.



## Non-small cell lung cancer with a single metastasis, the new stage M1b; does the site matter?



Michiel J.E.G.W. Vanfleteren<sup>a,\*</sup>, Lizza E.L. Hendriks<sup>a</sup>, Mathijs J.C. Weijnen<sup>a</sup>, Stefan A. Voo<sup>b</sup>,  
Monique M.H. Hochstenbag<sup>a</sup>, Anne-Marie C. Dingemans<sup>a</sup>

<sup>a</sup> Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands

<sup>b</sup> Department of Nuclear Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands

### ARTICLE INFO

#### Keywords:

Non-small cell lung cancer  
Oligometastasis  
TNM8  
staging

### ABSTRACT

Non-small cell lung cancer (NSCLC) patients with a solitary metastasis are considered to have a more favourable prognosis compared to those with multiple metastases. This is also shown in the 8<sup>th</sup> tumor, node, metastases edition for lung cancer (TNM8): patients with M1b (single extrapulmonary metastasis) have a superior prognosis than those with M1c disease (multiple metastases). Although not described in the TNM8, site of single metastatic disease may reflect tumour biology and may be of important prognostic value. We report a case of a patient with squamous cell NSCLC and a single skeletal muscle metastasis with a remarkably aggressive disease course.

### Main text

#### Case description

A 62-year-old woman, former smoker (50 pack years), without other medical history, was referred because of a painful lump in the left upper arm. Her World Health Organisation performance status (WHO-PS) was 0. Except for a palpable ill-defined lump, firmly attached to the proximal biceps muscle underneath, physical examination was normal. Laboratory results were normal. A work-up with imaging and biopsy revealed an irresectable squamous cell carcinoma originating from the biceps muscle. Staging with 18-fluodeoxyglucose positron emission tomography-computed tomography (<sup>18</sup>FDG-PET-CT) revealed two suspicious nodules in the right lower lobe, but no lymphadenopathy or other distant metastases (Fig. 1). CT-guided biopsy of the cavitating pulmonary nodule showed squamous cell NSCLC with comparable morphological features. Endobronchial ultrasound was not performed in absence of enlarged or <sup>18</sup>FDG-avid lymph nodes and peripheral pulmonary tumour sites in according to the ESMO guideline [1]. In our multidisciplinary team the cancer was staged as cT3N0M1b, stage IVA (TNM8) NSCLC with a single muscle metastasis and it was decided to treat both the lung lesion and the muscle metastasis with curative intent. Concurrent instead of sequential chemoradiation was chosen because of the very painful metastasis and the planned pain-reducing effect of the radiotherapy. However, the patient's clinical condition deteriorated rapidly to WHO-PS 4 in three weeks from diagnosis due to

development of a deep venous thrombosis and a grade 4 hypercalcemia caused by bone invasion. Appropriate treatment could not improve her performance status. A second <sup>18</sup>FDG-PET-CT for radiation planning, performed four weeks after the staging <sup>18</sup>FDG-PET-CT, showed an impressive rapid progressive disease with extensive invasion of the soft tissue of the chest wall and humerus (Fig. 2). Six weeks after staging <sup>18</sup>FDG-PET-CT and only ten weeks after her first presentation to her general practitioner, the patient died.

### Discussion


In the last decade, there is an increasing interest in the field of radical treatment of oligometastatic disease. In TNM8, patients with M1b are considered a separate entity with a superior prognosis than those with M1c disease [2]. Low local disease burden (especially N0 disease) is associated with a superior prognosis in radically treated oligometastatic NSCLC [3]. Nevertheless, disease course in our patient with <sup>18</sup>FDG-PET-CT staged N0 disease and a solitary metastasis was very aggressive. According to the seed and soil hypothesis, tumor cells must acquire the ability to disseminate hematogenously by accumulating specific genetic mutations and, in turn, the microenvironment of the target organ must be permissive to tumor growth [4]. The muscle resistance for metastatic disease may therefore be indicative for an aggressive subtype of NSCLC [4,5]. Although not shown in TNM8, due to small patient numbers per organ, site of single metastatic disease may reflect tumour biology and may be of important prognostic value [2,6].

\* Correspondence to: Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), PO Box 5800, 6202 AZ Maastricht, The Netherlands.


E-mail addresses: [michielvanfleteren@msn.com](mailto:michielvanfleteren@msn.com) (M.J.E.G.W. Vanfleteren), [lizza.hendriks@mumc.nl](mailto:lizza.hendriks@mumc.nl) (L.E.L. Hendriks), [m.weijnen@student.maastrichtuniversity.nl](mailto:m.weijnen@student.maastrichtuniversity.nl) (M.J.C. Weijnen), [stefan.voo@mumc.nl](mailto:stefan.voo@mumc.nl) (S.A. Voo), [m.hochstenbag@mumc.nl](mailto:m.hochstenbag@mumc.nl) (M.M.H. Hochstenbag), [a.dingemans@mumc.nl](mailto:a.dingemans@mumc.nl) (A.-M.C. Dingemans).

<http://dx.doi.org/10.1016/j.ctarc.2017.07.003>

Received 26 April 2017; Received in revised form 13 July 2017; Accepted 25 July 2017  
2468-2942/ © 2017 Elsevier Ltd. All rights reserved.



**Fig. 1.** A. Attenuation-Corrected Positron Emission Tomography shows a mass in the left upper arm and a cavitating pulmonary nodule in right lower lobe. B. Fusion  $^{18}\text{F}$ FDG-PET-CT shows an intense  $^{18}\text{F}$ FDG-avid mass (6.0 cm diameter) in the soft tissue of the left arm. C. Fusion  $^{18}\text{F}$ FDG-PET-CT showing a cavitating pulmonary nodule with PET-positive margins (2.9 cm diameter) and the lower part of the muscle metastasis. D. Fusion  $^{18}\text{F}$ FDG-PET-CT shows a slight  $^{18}\text{F}$ FDG-avid pulmonary nodule in the right lower lobe (7 mm diameter).



**Fig. 2.** A. Fusion  $^{18}\text{F}$ FDG-PET-CT four weeks after the staging  $^{18}\text{F}$ FDG-PET-CT showing extensive growth and invasion of the solitary metastasis in the chest wall and humerus. B. Fusion  $^{18}\text{F}$ FDG-PET-CT four weeks after the staging  $^{18}\text{F}$ FDG-PET-CT showing growth of pulmonary cavitating tumour and the lower part of the muscle metastasis.

More prospective data on this topic are needed and the site of metastasis should be incorporated in the next TNM classification in order to better identify subgroups with favourable prognosis in whom treatment with curative intent should be considered and tested.

## Conclusions

Stage IV NSCLC, presenting with a single metastasis, especially with N0 disease, is considered to have a good prognosis. However, some metastatic sites may represent aggressive disease with poor prognosis. Prospective data are needed to further elucidate the importance of the site of single metastatic disease and potentially identify patient subgroups with more favorable prognosis.

## Clinical practice points

In case of NSCLC with a single extrathoracic metastasis, the new TNM8 M1b, no hard evidence exist for significant differences in prognosis according to the organ site of metastasis [2,6]. However, this case illustrates that metastatic site may be of important prognostic value. This issue should be addressed in the next TNM classification in order to better identify subgroups with favourable prognosis in whom treatment with curative intent should be considered and tested.

## Acknowledgement

The authors wish to thank R. Wanders, department of radiotherapy, MAASTRO Clinic, Maastricht, the Netherlands for the selection and preparation of artwork.

## Disclosure of funding

We have nothing to disclose.

## Conflict of interest

Michiel J.E.G.W. Vanfleteren has nothing to disclose.

Lizza E.L. Hendriks reports grants and personal fees from Roche, personal fees from MSD, personal fees from AstraZeneca, personal fees from BMS, personal fees from Boehringer Ingelheim, outside the submitted work.

Mathijs J.C. Weijnen has nothing to disclose.

Stefan A. Voo has nothing to disclose.

Monique M.H. Hochstenbag has nothing to disclose.

Anne-Marie C. Dingemans has nothing to disclose.

## References

- [1] W.E. Eberhardt, et al. Proceedings of the 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. *Ann. Oncol.*, 26(8): p. 1573–1588, 2015.
- [2] W.E. Eberhardt, et al., The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer, *J. Thorac. Oncol.* 10 (11) (2015) 1515–1522.
- [3] A.B. Ashworth, et al., An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer, *Clin. Lung Cancer* 15 (5) (2014) 346–355.
- [4] I.J. Fidler, G. Poste, The "seed and soil" hypothesis revisited, *Lancet Oncol.* 9 (8) (2008) 808.
- [5] J.B. Strauss, et al., Psoas muscle metastases in non-small cell lung cancer, *J. Thorac. Dis.* 4 (1) (2012) 83–87.
- [6] L.E. Hendriks, et al., Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: results from a population-based study, *Eur. J. Cancer* 51 (17) (2015) 2534–2544.